Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.

Jyh-Jou ChenPei-Lun LeeHung-Chih ChiuHung-Da TungYen-Cheng ChiuPin-Nan Cheng

Published in: Journal of gastroenterology and hepatology (2019)

The high SVR and excellent safety of LDV/SOF treatment for GT6 CHC patients suggest that LDV/SOF is a favorable option for treating GT6 CHC patients in Taiwan and Asia.

Keyphrases

ejection fraction
newly diagnosed
prognostic factors
patient reported outcomes
patient reported